Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)

Abstract

The legend for Fig. 4 has published as “Skin improvements in two patients treated with lebrikizumab. a Antecubital fossa and b hand at baseline and at 2, 8, and 16 weeks of lebrikizumab treatment. Corresponding values and percent improvements from baseline in EASI, Pruritus NRS, POEM, and DLQI are listed below each photo.